Loan & DebtJul 17, 2026, 04:27 PM
Xeris Biopharma Eliminates All $33.5M Convertible Senior Notes
AI Summary
Xeris Biopharma Holdings, Inc. announced the completion of previously disclosed exchange transactions and a separate conversion of its 8.00% Convertible Senior Notes due 2028. The company exchanged approximately $23 million in principal amount of notes for 5.0 million shares of common stock and $23 million in cash. Additionally, a holder converted $10.5 million in notes into 3.6 million shares, resulting in no 2028 Notes remaining outstanding.
Key Highlights
- Completed exchange transactions and conversion of 2028 Notes on July 15, 2026.
- Exchanged $23 million in 2028 Notes for 5.0 million shares and $23 million cash.
- Separately, $10.5 million in 2028 Notes converted into 3.6 million shares.
- All 2028 Notes, totaling $33.5 million, are no longer outstanding.
- Shares issued in exchange were unregistered, relying on Section 4(a)(2) exemption.
- Shares issued in conversion were unregistered, relying on Section 3(a)(9) exemption.
Price Impact
More from XERS